Dermatitis News

Rinvoq monotherapy has met its primary and secondary endpoints in a phase 3 study for the treatment of moderate to severe atopic dermatitis, according to a press release from AbbVie.

Potassium iodide offers a rapid response in the treatment of erythema nodosum and may be an adequate option for patients who do not respond to the standard of care, according to a presentation at the Interdisciplinary Autoimmune Summit.

A regimen of dupilumab and a corticosteroid may be beneficial for preteen children with severe atopic dermatitis, according to findings presented at the American Academy of Dermatology virtual meeting.

The FDA has accepted a biologics license application for tralokinumab for the treatment of moderate to severe atopic dermatitis in adults, Leo Pharma announced in a press release.

Subcutaneous nemolizumab combined with topical agents reduced pruritus in Japanese patients with atopic dermatitis, according to phase 3 trial results published in the New England Journal of Medicine.

Enrollment is complete in a phase 2 proof of concept clinical trial for roflumilast foam for the treatment of seborrheic dermatitis, Arcutis Biotherapeutics announced in a press release.

The use of abrocitinib in the treatment of moderate to severe atopic dermatitis was beneficial while lowering the risk for adverse events, according to findings presented at the American Academy of Dermatology virtual meeting.

Patients with allergic diseases may have an increased risk for developing psoriasis, according to study results presented at the American Academy of Dermatology virtual meeting.

The Dupixent prefilled pen has been approved by the FDA for all Dupixent indications in patients aged 12 years and older, Regeneron announced in a press release.

Tralokinumab 300 mg showed significant improvements in pruritus and quality of life in atopic dermatitis patients in three phase 3 trials, according presentations at the American Academy of Dermatology virtual meeting.